Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...

Presenter: Saman Nazarian, MD, Brigham and Women's Hospital (Boston, Massachusetts) (Dr Nazarian is currently a fellow at Johns Hopkins Hospital in Baltimore, Maryland.) The ultimate cause of death in ...

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart failure ...

Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...

The majority of studies with CHF patients have utilized a combined training protocol of resistance and endurance exercises. Of these, two studies did not include control groups. [9,10] Delagardelle et ...

Four out of the five patients in the low-dose group have shown improvements in New York Heart Association (NYHA) heart failure classification at 6 months, with clinically meaningful improvements in ...

AB-1002 is administered via antegrade intracoronary artery infusion. The Food and Drug Administration (FDA) has granted Fast Track designation to AB-1002 for the treatment of congestive heart failure ...